33538-98-6

Basic information

• Product Name: 3-(5-chloro-2-hydroxyphenyl)acrylaldehyde
• Synonyms: 3-(5-chloro-2-hydroxyphenyl)acrylaldehyde;(E)-3-(5-Chloro-2-hydroxyphenyl)acrylaldehyde
• CAS NO: 33538-98-6
• Molecular Formula: C₉H₇ClO₂
• Molecular Weight: 182.61
• EINECS: -0
• Mol File: 33538-98-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 353.1°Cat760mmHg
• Flash Point: 167.3°C
• Appearance: /
• Density: 1.322g/cm³
• Vapor Pressure: 1.81E-05mmHg at 25°C
• Refractive Index: 1.629
• CAS DataBase Reference: 3-(5-chloro-2-hydroxyphenyl)acrylaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-chloro-2-hydroxyphenyl)acrylaldehyde(33538-98-6)
• EPA Substance Registry System: 3-(5-chloro-2-hydroxyphenyl)acrylaldehyde(33538-98-6)

Safety Data

• Hazardous Substances Data: 33538-98-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H7ClO2/c10-8-3-4-9(12)7(6-8)2-1-5-11/h1-6,12H/b2-1+

Upstream product

• 33538-95-3 5-Chlor-2-acetoxyzimtaldehyd 
• 635-93-8 5-chlorosalicyclaldehyde 
• 2136-75-6 (triphenylphosphoranylidene)acetaldehyde 
• 2420-26-0 4-chlorosalicylaldehyde 

Relevant articles and documents

Application of E1cB Elimination in Asymmetric Organocatalytic Cascade Reactions to Construct Polyheterocyclic Compounds

By introducing a carbon functionality at 2-position of chromane, the formal asymmetric functionalization of the 3-position of 2-substituted chromane has been realized via a highly chemo-, regio-, and stereoselective organocatalytic cascade reaction in a sequential one-pot manner involving an E1cB mechanism governed ring-opening process. Critical to our success was the design of a chiral dipeptide-based bifunctional acid-base organocatalyst, which exhibited high catalytic activity at low catalyst loading (1-0.1 mol %), leading to biologically interesting polyheterocyclic compounds.

SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES

Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I or compounds of Formula I′: In particular, provided herein are processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions comprising, and therapeutic methods comprising administering such compounds. In particular, provided herein are compounds for the treatment of pain and diabetes.

SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN

Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I: In particular, provided herein are processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions comprising, and therapeutic methods comprising administering such compounds. In particular, provided herein are compounds for the treatment of pain.